irbesartan + trichlormethiazide

**Irbesartan + trichlormethiazide** is an oral fixed-dose antihypertensive combination developed by Shionogi as **S-474474** and marketed in Japan as **IRTRA Combination Tablets LD/HD**. It combines irbesartan, a selective angiotensin II type 1 receptor blocker that suppresses angiotensin II-mediated vasoconstriction and aldosterone signaling, with trichlormethiazide, a thiazide diuretic that inhibits renal sodium chloride reabsorption. The combination was approved in Japan on June 28, 2013 for hypertension and is supplied as tablet formulations containing irbesartan with trichlormethiazide. ([shionogi.com](https://www.shionogi.com/global/en/news/2013/06/130628.html))

Brand names

IRTRA Combination Tablets HDIRTRA Combination Tablets LDイルトラ配合錠HDイルトラ配合錠LD

Other names

irbesartan/trichlormethiazidetrichlormethiazide + irbesartanイルベサルタン・トリクロルメチアジド配合剤